Voyager Therapeutics, Inc. (VYGR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q3 '16: 16.8M Q4 '16: 14.2M Q1 '17: 10.9M Q2 '17: 8.3M Q3 '17: 6.2M Q4 '17: 10.1M Q1 '18: 9.6M Q2 '18: 11M Q3 '18: 12M Q4 '18: 7.6M Q1 '19: 11.9M Q2 '19: 55.4M Q3 '19: 73.7M Q4 '19: 104.4M Q1 '20: 117.3M Q2 '20: 99.9M Q3 '20: 197.3M Q4 '20: 171.1M Q1 '21: 159.6M Q2 '21: 132.2M Q3 '21: 15.9M Q4 '21: 37.4M Q1 '22: 31.6M Q2 '22: 30.9M Q3 '22: 70.5M Q4 '22: 40.9M Q1 '23: 190.7M Q2 '23: 194.9M Q3 '23: 158.4M Q4 '23: 250M Q1 '24: 119M Q2 '24: 143.8M Q3 '24: 163.8M Q4 '24: 80M Q1 '25: 67M Q2 '25: 42.6M Q3 '25: 31.3M Q4 '25: 40.4M Q1 '26: 36.5M Q2 '26: 34.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -34.9M Q4 '16: -41.3M Q1 '17: -51.4M Q2 '17: -60.4M Q3 '17: -73.4M Q4 '17: -71.9M Q1 '18: -75.4M Q2 '18: -82.5M Q3 '18: -80.3M Q4 '18: -91.1M Q1 '19: -99.3M Q2 '19: -64.4M Q3 '19: -61.1M Q4 '19: -51.7M Q1 '20: -46.8M Q2 '20: -65M Q3 '20: 37.3M Q4 '20: 27.4M Q1 '21: 26.2M Q2 '21: 6.6M Q3 '21: -103M Q4 '21: -73.6M Q1 '22: -69.4M Q2 '22: -60.2M Q3 '22: -20.6M Q4 '22: -50.8M Q1 '23: 93.4M Q2 '23: 87.3M Q3 '23: 43.4M Q4 '23: 122M Q1 '24: -17.1M Q2 '24: -6.7M Q3 '24: 9.1M Q4 '24: -83.3M Q1 '25: -101.8M Q2 '25: -123.4M Q3 '25: -140.2M Q4 '25: -131.8M Q1 '26: -127.4M Q2 '26: -117.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -32.8M Q4 '16: -40.2M Q1 '17: -49.7M Q2 '17: -59.2M Q3 '17: -73.5M Q4 '17: -70.7M Q1 '18: -74M Q2 '18: -80.6M Q3 '18: -77.6M Q4 '18: -88.3M Q1 '19: -95.5M Q2 '19: -58.8M Q3 '19: -53.6M Q4 '19: -43.6M Q1 '20: -40.7M Q2 '20: -60.5M Q3 '20: 40.1M Q4 '20: 36.7M Q1 '21: 39.4M Q2 '21: 17.9M Q3 '21: -92.8M Q4 '21: -71.2M Q1 '22: -70.9M Q2 '22: -59.8M Q3 '22: -17.1M Q4 '22: -46.4M Q1 '23: 99M Q2 '23: 95.8M Q3 '23: 52.3M Q4 '23: 132.3M Q1 '24: -3M Q2 '24: 9M Q3 '24: 25.9M Q4 '24: -65M Q1 '25: -84.7M Q2 '25: -107.9M Q3 '25: -126.8M Q4 '25: -119.7M Q1 '26: -116.6M Q2 '26: -107.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -38.9M Q4 '16: -42.5M Q1 '17: -47.3M Q2 '17: -53.9M Q3 '17: -59.6M Q4 '17: -61.4M Q1 '18: 1.6M Q2 '18: -4.6M Q3 '18: -6.4M Q4 '18: -15.9M Q1 '19: 60.7M Q2 '19: 51.6M Q3 '19: 47.7M Q4 '19: 48.7M Q1 '20: -105.3M Q2 '20: -94.9M Q3 '20: -98.1M Q4 '20: -96.7M Q1 '21: -89.2M Q2 '21: -90.7M Q3 '21: -86.7M Q4 '21: -53.5M Q1 '22: 2.2M Q2 '22: 6.4M Q3 '22: 10.9M Q4 '22: -12.5M Q1 '23: 76.6M Q2 '23: 94.3M Q3 '23: 89.4M Q4 '23: 77.9M Q1 '24: 13.1M Q2 '24: -17.6M Q3 '24: -24.5M Q4 '24: -15.3M Q1 '25: -112M Q2 '25: -113.7M Q3 '25: -116.7M Q4 '25: -132.5M Q1 '26: -128M Q2 '26: -120.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -40.2M Q4 '16: -47.5M Q1 '17: -54.8M Q2 '17: -61.7M Q3 '17: -67.3M Q4 '17: -65.3M Q1 '18: -1.1M Q2 '18: -8.1M Q3 '18: -10.3M Q4 '18: -20.2M Q1 '19: 56.9M Q2 '19: 47.1M Q3 '19: 42.8M Q4 '19: 40.9M Q1 '20: -113.4M Q2 '20: -102.9M Q3 '20: -110M Q4 '20: -108.8M Q1 '21: -100.2M Q2 '21: -100M Q3 '21: -91.5M Q4 '21: -55.1M Q1 '22: 923K Q2 '22: 4.1M Q3 '22: 9M Q4 '22: -15M Q1 '23: 73.7M Q2 '23: 91.3M Q3 '23: 86M Q4 '23: 74.7M Q1 '24: 8.2M Q2 '24: -22.3M Q3 '24: -28.7M Q4 '24: -18.8M Q1 '25: -114M Q2 '25: -115.8M Q3 '25: -118.9M Q4 '25: -135.1M Q1 '26: -129.9M Q2 '26: -121.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '18: 32M Q2 '19: 37.9M Q3 '19: 36.7M Q2 '20: 37M Q3 '20: 37.7M Q1 '21: 37.5M Q2 '21: 37.6M Q3 '21: 37.8M Q1 '22: 38M Q2 '22: 38.3M Q3 '22: 39.6M Q1 '23: 42.2M Q2 '23: 43.5M Q3 '23: 43.9M Q1 '24: 57.1M Q2 '24: 57.7M Q3 '24: 57.9M Q1 '25: 58.3M Q2 '25: 58.7M Q3 '25: 58.8M Q1 '26: 59.5M Q2 '26: 60.5M Q2 '18 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '16: -0.34 Q4 '16: -0.44 Q1 '17: -0.80 Q2 '17: -1.16 Q3 '17: -1.70 Q4 '17: -2.67 Q1 '18: -2.65 Q2 '18: -2.72 Q3 '18: -2.46 Q4 '18: -2.76 Q1 '19: -2.94 Q2 '19: -1.85 Q3 '19: -1.63 Q4 '19: -1.27 Q1 '20: -1.12 Q2 '20: -1.64 Q3 '20: 1.04 Q4 '20: 0.98 Q1 '21: 1.06 Q2 '21: 0.49 Q3 '21: -2.45 Q4 '21: -1.89 Q1 '22: -1.87 Q2 '22: -1.57 Q3 '22: -0.45 Q4 '22: -1.23 Q1 '23: 2.27 Q2 '23: 2.26 Q3 '23: 1.22 Q4 '23: 3.03 Q1 '24: -0.11 Q2 '24: 0.22 Q3 '24: 0.65 Q4 '24: -1.14 Q1 '25: -1.47 Q2 '25: -1.86 Q3 '25: -2.17 Q4 '25: -2.04 Q1 '26: -1.98 Q2 '26: -1.81 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.